ELYMUS - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | - | 1,111,033 | 1,796,447 | 1,606,753 | 1,412,609 | 1,716,505 | 1,007,393 | 1,024,067 |
| Profit before tax | 0 | 133,289 | 562,162 | 302,306 | 167,808 | 289,867 | 93,874 | 143,333 |
| Net profit | 0 | 119,281 | 490,505 | 257,528 | 137,762 | 250,018 | 86,367 | 118,710 |
| Equity | 954,974 | 1,070,855 | 1,411,361 | 1,368,889 | 1,119,651 | 1,019,669 | 806,036 | 924,746 |
| Liabilities | 795,797 | 249,181 | 647,825 | 285,071 | 592,960 | 598,132 | 555,308 | 365,150 |
| Non-current assets | 427,536 | 449,966 | 415,173 | 392,604 | 361,905 | 333,539 | 375,665 | 362,406 |
| Current assets | 1,318,593 | 867,432 | 1,656,971 | 1,268,075 | 1,387,473 | 1,287,109 | 999,665 | 926,002 |
| Total assets | 1,746,129 | 1,317,398 | 2,072,144 | 1,660,679 | 1,749,378 | 1,620,648 | 1,375,330 | 1,288,408 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 387,752 | 317,165 | 309,135 |
| Social insurance contributions | - | - | - | - | - | 31,516 | 36,005 | 38,852 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | - | +61.7% | -10.6% | -12.1% | +21.5% | -41.3% | +1.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 0.0% | 9.1% | 23.7% | 15.5% | 7.9% | 15.4% | 6.3% | 9.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 0.0% | 11.1% | 34.8% | 18.8% | 12.3% | 24.5% | 10.7% | 12.8% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | 10.7% | 27.3% | 16.0% | 9.8% | 14.6% | 8.6% | 11.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | 12.0% | 31.3% | 18.8% | 11.9% | 16.9% | 9.3% | 14.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.8 | 0.2 | 0.5 | 0.2 | 0.5 | 0.6 | 0.7 | 0.4 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 124,601 | 222,242 | 205,118 | 176,576 | 214,563 | 125,924 | 128,008 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
ELYMUS - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-12-18 | 2023-12-20 | 12.85 |
ELYMUS - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
ELYMUS, UAB (code 122043642) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated EUR 1.02 million in revenue, slightly above the EUR 1.01 million recorded in 2024, while remaining below the EUR 1.72 million achieved in 2023. Net profit improved to EUR 118.7 thousand in 2025 from EUR 86.4 thousand in 2024, though it was still lower than the EUR 250.0 thousand reported in 2023. The 2025 profit margin was 11.6%, compared with 8.6% in 2024 and 14.6% in 2023, indicating a partial recovery in profitability. At year-end 2025, total assets stood at EUR 1.29 million, equity at EUR 924.7 thousand and liabilities at EUR 365.1 thousand. The company’s equity ratio was 71.8%, debt-to-equity 0.39, asset turnover 0.79x, ROE 12.8% and ROA 9.2%. Revenue per employee was EUR 128.0 thousand, with profit per employee of EUR 14.8 thousand.